The US pharmaceutical contract manufacturing is anticipated to grow at a considerable of 4.8% CAGR during the forecast period (2021-2027). The rising investments in R&D is one of the prime factors affecting and driving the market. In the US the spending in R&D is more in pharmaceutical and biotechnology market. The outsourcing of services by companies dealing in pharma sector in the US has increased in order to improve their margins related to profits. For this purpose, the companies are investing more in R&D due to increasing technological complexity with regards to development of drugs along with inject-able and sterile liquid dose to form.
A full report of US Pharmaceutical Contract Manufacturing Market is available at: https://www.omrglobal.com/industry-reports/us-pharmaceutical-contract-manufacturing-market
To gain on the opportunity key players operating in the US pharmaceutical contract manufacturing had been adopting strategy such as new launches in the country. For instance, in November 2020, Catalent, Inc. which is one of the providers of advanced delivery technology along with manufacturing solutions for consumer health products and various therapies have notified the acquisition of bone therapeutics cell therapy manufacturing subsidiary named as Skeletal Cell Therapy Support SA (SCTS). This will enable the company to expand its capabilities related to cell therapy.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/us-pharmaceutical-contract-manufacturing-market
Market Coverage
• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered-
o By Category
o By Product
o By Services
- Competitive Landscape- AbbVie Inc., Cardinal Health., Catalent, Inc., Pfizer Inc., and Thermo Fisher Scientific Inc.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
US Pharmaceutical Contract Manufacturing – Segmentation
By Category
• Human Based Drugs
• Animals Based Drugs
By Product
• Over-The-Counter (OTC) Drugs
• Active Pharmaceutical Ingredients (API)
• Finished Dosage Formulation
• Other
By Services
• Manufacturing Services
• Non-Clinical Services
• Research and Development
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
